Boston Scientific receives FDA approval on improved stroke-reducing technology
Photo | Courtesy Boston Scientific
Boston Scientific headquarters in Marlborough
Marlborough medical device titan Boston Scientific received approval from the U.S. Food and Drug Administration for an upgrade to its WATCHMAN technology, which is designed to reduce the risk of strokes in patients.
The WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device builds on the technology of its WATCHMAN FLX LAAC device which was approved in July 2020 and has been used in nearly 190,000 of the more than 300,000 WATCHMAN procedures successfully completed to date globally, according to a Wednesday press release from Boston Scientific.
The device includes improvements which make the device easier to install for doctors, and improves the patient’s ability to heal after the procedure, according to the press release
"We are pleased to introduce U.S. clinicians to our newest LAAC technology, which is designed to enhance post-procedural healing, improve the precision of WATCHMAN FLX Pro implants, and expand the size range of treatable appendages," Boston Scientific’s group president, Cardiology Joseph Fitzgerald, said in the press release. "These enhancements to our WATCHMAN FLX technology will enable efficiency during implant procedures and allow physicians to optimize treatment for their patients."
Boston Scientific is a publicly-traded company on the New York Stock Exchange with a market capitalization of nearly $80 billion as of Thursday morning. The company reported nearly $12.7 billion in revenues in 2022.
Boston Scientific employs 2,200 people in Central Massachusetts and 45,000 worldwide, according to the WBJ Research Department.
WBJ Web Partners
Most Recent
Most Recent
0 Comments